ZS Genetics, Hitachi High partner to develop, commercialise new DNA sequencing platform

8 March 2017 (Last Updated March 8th, 2017 18:30)

ZS Genetics has entered into a strategic collaboration with Hitachi High Technologies America (HTA), to develop and commercialise its new single molecule DNA sequencing platform.

ZS Genetics has entered into a strategic collaboration with Hitachi High Technologies America (HTA), to develop and commercialise its new single molecule DNA sequencing platform.

It is expected that the high-resolution electron microscopy (EM) will enable the sequencing of high-quality long reads (50,000+ base-pairs) of single DNA molecules.

ZS Genetics chief executive officer John McCarthy said: “The technical capabilities of our two companies are expected to produce a DNA sequencing platform capable of enabling unique scientific discovery, as well as offering a powerful tool to complement and broaden current short-read sequencing technologies.

"Combining ZS Genetics’ proprietary long-read technologies with HTA's leadership in high-resolution EM is expected to accelerate the introduction of this important technology into leading scientific institutions."

"Combining ZS Genetics’ proprietary long-read technologies with HTA's leadership in high-resolution EM is expected to accelerate the introduction of this important technology into leading scientific institutions.”

Later this year, ZS Genetics intends to initiate an early-access centre in its Wakefield, Massachusetts facility for product and application development in collaboration with select customer and supply-chain partners.

HTA Nanotechnology Systems Division vice-president and general manager Phil Bryson said: “We are confident that HTA’s decades-long leadership in high-resolution EM for highly complex applications in R&D and industry can translate readily into this powerful and important new application for the life sciences industry.”

ZS Genetics' DNA sequencing technology platform combines high-resolution electron microscopy with DNA sample preparation to generate long-read high-quality, single-molecule DNA sequence information.

The platform is expected to allow scientific discovery across the complex diseases, expedite the discovery and complement the existing short-read DNA sequencing technologies.